COMPARE THE EVIDENCE

TB-500

Findings, possible implications, and reported experiences.

About TB-500

PeptideSkin & repair

Primary research area: Tissue repair · wound research
Regulatory status: Investigational / research only
Evidence level: Preclinical · limited human
Primary mechanism: Thymosin-beta-4-related actin and cell-migration biology; product identity varies

Reference profile available · Coverage varies by section

Also known as TB500

TB-500 is a research label commonly associated with a thymosin beta-4 fragment or analogue. It should not be silently treated as identical to endogenous full-length thymosin beta-4 or to every product sold under that name. [1][2]

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Animal · Reading scope not recorded

What did the tendon-repair experiment actually measure?

A product labeled TB-500 increased median tendon failure load versus control in repaired rat Achilles tendons. Combining it with BPC-157 did not outperform the separate treatments.

Limits: Very small groups; product identity and the rat model limit translation. This is not evidence of improved human recovery.

Open primary source · Read interpretation separately

Explore outcomes for this compound

Uses & research: Thymosin beta-4-related research has examined wound healing and cell migration, including clinical trial programs for specific ophthalmic or dermal preparations. Those results do not establish the identity, efficacy or safety of an injectable TB-500 product. [1][2]
Known half-life: No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: Product identity, human pharmacokinetics and long-term safety for TB-500 are not established in the sources used here. Results from a thymosin beta-4 preparation cannot be assumed to apply to an unapproved analogue. [1][2]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Product identity, human pharmacokinetics and long-term safety for TB-500 are not established in the sources used here. Results from a thymosin beta-4 preparation cannot be assumed to apply to an unapproved analogue.

Thymosin beta-4 wound-healing review ClinicalTrials.gov NCT00598871

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: TB-500 · tb500

Searchable names: TB500

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

1. Thymosin beta-4 wound-healing review Review · thymosin beta-4 biology and clinical development
2. ClinicalTrials.gov NCT00598871 Trial registry · specific thymosin beta-4-related preparation

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…